Dr. Ghosh on Global Trials With Zanubrutinib in MCL and NHL


Nilanjan Ghosh, MD, PhD, discusses global trials examining zanubrutinib in mantle cell lymphoma and non-Hodgkin lymphoma.

Nilanjan Ghosh, MD, PhD, director of the Lymphoma Program and a physician with Levine Cancer Institute, discusses global trials examining zanubrutinib (Brukinsa) in mantle cell lymphoma (MCL) and non-Hodgkin lymphoma (NHL).

Several studies of interest are being done with zanubrutinib, says Ghosh. For example, 2 phase 2 studies with zanubrutinib are being conducted in patients with relapsed/refractory MCL; 1 study was done in Australia which included patients with MCL and the other study was done in China, primarily in patients with MCL. The overall response rate with the agent was around 84% and the median progression-free survival was around 17 months. The most common adverse effects observed in these studies were cytopenias, rash, and infections. Hypertension was also reported, which is similar to what is reported with most BTK inhibitors, although it was less frequently reported.

Although atrial fibrillation has been reported with other BTK inhibitors, in this study, it was not reported. However, that does not mean atrial fibrillation with zanubrutinib will never occur. In this study, atrial fibrillation was also not seen within the duration of follow-up. In the pooled analysis of patients with NHL, there was also a low rate of atrial fibrillation was reported with zanubrutinib, concludes Ghosh.

Related Videos
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
Chul Kim, MD, MPH
Neil D. Gross, MD, FACS
Dae Won Kim, MD, Gastrointestinal Oncology Program, Moffitt Cancer Center